Allergan Demands FDA Retract Generic Restasis Guidance
With generic competition looming, Allergan Inc. on Monday released a letter decrying the U.S. Food and Drug Administration's proposal not to require human testing for generic versions of dry-eye medicine Restasis,...To view the full article, register now.
Already a subscriber? Click here to view full article